Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02301156
Title Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors TG Therapeutics, Inc.
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Ublituximab

Ibrutinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST